Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial



Furtado, Remo HM, Raz, Itamar, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Aylward, Philip, Dalby, Anthony J
et al (show 10 more authors) (2022) Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. CIRCULATION, 145 (21). 1581 - 1591.

[img] Text
DECLARE Blood Pressure Manuscript - Circulation Revision 1 Clean.docx - Accepted Version
Access to this file is embargoed until 5 November 2022.

Download (1MB)
Item Type: Article
Uncontrolled Keywords: blood pressure, dapagliflozin, diabetes mellitus, type 2, heart failure, sodium-glucose transporter 2 inhibitors, treatment outcomes
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 16 May 2022 14:32
Last Modified: 02 Sep 2022 01:11
DOI: 10.1161/CIRCULATIONAHA.121.058103
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3154848